Between October 18–21, this website will move to a new web address (from health.gov to odphp.health.gov). During that time, some functions might not work as expected. We appreciate your patience and understanding as we’re working to make this transition as smooth as possible.

Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices

About this resource:

Non-Systematic Review

Source: Centers for Disease Control and Prevention

Last Reviewed: March 2015

This report updates the Advisory Committee on Immunization Practices’ (ACIP) recommendation for human papillomavirus (HPV) vaccination to include the 9-valent HPV vaccine (9vHPV) as 1 of 3 available for routine vaccination, along with the 2-valent and 4-valent HPV vaccines. 9vHPV offers protection against 9 different types of HPV.

ACIP recommends:

  • 9vHPV, 4vHPV, or 2vHPV for routine vaccination of females age 11 or 12 years and females through age 26 years who haven’t been vaccinated previously, or who haven’t completed the 3-dose series
  • 9vHPV or 4vHPV for routine vaccination of males age 11 or 12 years and males through age 21 years who haven’t been vaccinated previously, or who haven’t completed the 3-dose series
  • 9vHPV or 4vHPV to vaccinate men who have sex with men and immunocompromised people (including those with HIV infection) through age 26 years, if not vaccinated previously
Read more about this resource

Objectives related to this resource (2)

Suggested Citation

1.

Petrosky E, Bocchini JA, Hariri S, et al. (2015). Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices. Retrieved from https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a3.htm.